Hologic, Inc.

Hologic, Inc.

HOLX
Hologic, Inc.US flagNASDAQ Global Select
76.01
USD
+0.00
- -
16.97BMarket Cap
Hologic, Inc.
HOLX
(NASDAQ Global Select)

Recent

price

76.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.49
6.85
7.58
9.28
9.19
9.64
10.11
10.93
11.7
12.5
14.37
21.91
19.33
16.33
17.1
18.13
18.37
Revenue per Share
-0.24
0.6
-0.28
-4.36
0.06
0.47
1.18
2.7
-0.4
-0.76
4.24
7.28
5.18
1.85
3.35
2.5
2.42
Basic EPS, GAAP
1.58
1.52
1.09
1.5
1.55
2.52
2.5
-0.35
2.28
1.99
2.82
8.81
8.23
4.02
5.16
4.26
4.51
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-9.76
-9.07
-9.24
-13.45
-13.06
-12.35
-11.19
-8.51
-9.06
-9.97
-5.98
1.17
6.37
8.34
12.09
15.1
15.99
Book Value per Share
-5.91
-5.53
-20.01
-17.79
-15.18
-13.37
-11.83
-11.29
-9.1
-7.08
-4.79
-2.81
1.43
3.43
3.57
3.62
4.68
Tangible Book Value per Share
259
261
264
269
275
281
280
280
275
269
263
257
252
247
236
226
225
Basic Weighted Avg Shares
1,680
1,789
2,003
2,492
2,531
2,705
2,833
3,059
3,218
3,367
3,776
5,632
4,863
4,030
4,030
4,100
4,126
Sales/Revenue/Turnover
10.82
16.87
12.41
11.29
13.32
17.88
19.74
15.82
15.79
-0.31
29.79
44.08
33.54
18.89
23.1
19.15
19.21
Operating Margin (%)
295
305
346
516
523
491
465
449
480
463
376
407
430
323
309
300
295
Depreciation Expense
-63
157
-74
-1,173
17
132
331
756
-111
-204
1,115
1,872
1,302
456
790
566
544
Net Income, GAAP
- -
30.89
- -
- -
64.03
25.73
20.35
38.6
- -
- -
- -
20.81
18.02
32.55
8.74
16.96
18.03
Effective Tax Rate (%)
-3.74
8.78
-3.68
-47.06
0.68
4.87
11.68
24.7
-3.46
-6.05
29.53
33.23
26.77
11.31
19.59
13.8
13.18
Profit Margin (%)
657
833
902
536
946
322
425
-387
321
723
983
1,842
2,924
2,977
2,786
2,691
2,892
Working Capital
1,447
1,521
5,004
4,276
4,187
3,255
3,084
2,229
2,761
2,836
2,797
2,801
2,880
2,594
2,593
2,593
2,511
LT Debt
2,699
2,937
2,961
1,942
2,063
2,079
2,143
2,785
2,429
2,116
2,707
4,219
4,876
5,017
5,130
5,048
5,245
Total Equity
- -
4.83
- -
- -
1.84
5.94
7.9
5.05
- -
- -
- -
29.47
17.59
6.52
10.78
8.4
8.66
Return on Invested Capital (%)
- -
-24.61
- -
- -
10.02
64.3
213.93
136.32
- -
- -
- -
77.51
34.63
11.19
17.21
11.48
10.89
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
136.72
24.9
32.17
18.06
16.37
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Jun'25
Sep'25
Dec'26
ST Debt
3
33
9
LT Borrowings
2,509
2,505
2,503
LT Finance Leases
10
88
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
222
223
223
Market Capitalization
14,891
15,263
16,737

Working Capital

FRC

in mil. unless spec.
Jun'25
Sep'25
Dec'26
Total Current Assets
3,421
3,668
3,843
Cash, Cash Equivalents & STI
1,879
2,203
2,365
Accounts Receivable, Net
609
601
584
Inventories
714
679
688
Total Current Liabilities
962
977
951
Payables & Accruals
746
450
771
ST Debt
3
33
9
Deferred Revenue
213
200
171

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.03%
14.99%
-1.6%
Free Cash Flow
-67.64%
29.41%
-20.86%
Net Income, GAAP
-38.26%
3.44%
-28.35%
Sales/Revenue/Turnover
- -
- -
1.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,013
1,018
1,011
988
4,030
2025
1,022
1,005
1,024
1,050
4,100
2026
1,048
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.03
0.72
0.83
0.76
3.35
2025
0.87
-0.08
0.87
0.83
2.5
2026
0.8
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products focused on women's health. The company operates through four primary segments: Diagnostics, offering molecular diagnostic assays such as Aptima for women's health screening including HPV and STI testing, as well as blood screening solutions; Breast Health, providing digital mammography systems like Selenia Dimensions 3D, Genius AI detection technology, breast biopsy systems, and pathology solutions; GYN Surgical, featuring devices including the MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu radiofrequency ablation system, CoolSeal vessel sealing portfolio, and JustRight surgical stapler; and Skeletal Health, encompassing the Horizon DXA bone densitometry and Fluoroscan Insight FD mini C-arm systems. Founded in 1985 and headquartered in Marlborough, Massachusetts, Hologic serves healthcare providers and laboratories worldwide, with major revenue from the United States, Europe, and Asia. In October 2025, the company agreed to be acquired by private equity firms Blackstone and TPG for up to $79 per share in an $18.3 billion deal including debt, expected to close in the first half of 2026 pending approvals, marking a shift to private ownership to accelerate innovation and growth; recent developments also include expanding the Panther molecular diagnostics platform with Fusion add-on for enhanced PCR and TMA capabilities, development of new gastrointestinal and healthcare-associated infection assays, organizational enhancements in breast health sales execution, and the anticipated launch of the Envision mammography platform in 2026.

Company News

APIChat
  • OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay

  • New Evidence Backs Hologic's AI-Powered Mammography Technology for Detecting Challenging Cancers

  • Blackstone and TPG Complete Acquisition of Hologic

  • Hologic Target of Unusually Large Options Trading (NASDAQ:HOLX)

  • Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600

  • Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Go-Private Transaction

  • Exchange Traded Concepts LLC Lowers Position in Hologic, Inc. $HOLX

  • Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

  • Hologic (NASDAQ:HOLX) Hits New 52-Week High – Time to Buy?

  • HOLX vs. ALGN: Which MedTech Stock Is the Better Investment Pick Now?

  • Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

  • Hologic's Women's Health Index Flags Alarming Gaps in STI Screening

  • Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase?

  • 1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates

  • Cinctive Capital Management LP Buys 23,119 Shares of Hologic, Inc. $HOLX

  • Arrowpoint Investment Partners Singapore Pte. Ltd. Takes $576,000 Position in Hologic, Inc. $HOLX

  • What Drives Hologic's GYN Surgical Strength in a Competitive Market?

  • Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

  • Hologic's Diagnostics Strength in Focus: Is More Upside Ahead?

  • Becker Capital Management Inc. Boosts Holdings in Hologic, Inc. $HOLX